Generative AI-driven drug Rentosertib enters Phase III trial for idiopathic pulmonary fibrosis

	Pulmonology
	The latest pulmonology news from News Medical

	Generative AI-driven drug Rentosertib enters Phase III trial for idiopathic pulmonary fibrosis Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial (NCT07687459, CTR20262475) at Peking Union Medical College Hospital, while Shanghai Pulmonary Hospital has also enrolled its first patient on the same day.

	Rentosertib shifts multiple proteomic aging clocks toward younger age profiles in IPF trial Researchers applied six proteomic aging clocks to serum samples from a phase 2a trial of rentosertib in people with idiopathic pulmonary fibrosis and found treatment-associated shifts toward younger predicted biological-age profiles, particularly with the 30 mg twice-daily regimen.

			MRI surveillance alone improves outcomes for patients with small-cell lung cancer Results from the international phase III SWOG S1827 MAVERICK trial show that brain MRI surveillance alone improved cognitive failure-free survival compared with MRI surveillance plus prophylactic cranial irradiation (PCI) in patients with small-cell lung cancer (SCLC).

			Innovative device improves real-time monitoring of donated lungs More than three-quarters of donated lungs offered for transplantation are not used, according to the UK's National Institute for Health and Care Excellence, contributing to a chronic shortage of organs for patients with end-stage lung disease.

			More hospitals are adopting AI, yet the access gap is proving hard to close A national analysis of 6,166 US hospitals found that specific workflow AI capabilities were associated with higher sepsis bundle completion rates and lower 30-day pneumonia mortality, whereas robotics showed narrower procedural associations. Geographic access remained highly uneven, with about 114.

	Tirzepatide vs semaglutide for asthma: the difference was smaller than researchers expected In a US multicenter electronic health record study, researchers compared tirzepatide with semaglutide in adults with asthma and type 2 diabetes, matching 8,176 patients in each treatment group. Asthma exacerbation risk was similar between treatments, while tirzepatide was associated with a lower likelihood of receiving a short-acting beta-agonist prescription.

	New approach repairs airway barrier defects in cystic fibrosis A UNIGE team has succeeded in restoring the defective respiratory protective barrier in people with this rare genetic disease.

	Subcutaneous tarlatamab exhibits low toxicity rates in phase 1b trial Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), according to findings from the phase 1b DeLLphi-308 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

	Phase 2 study highlights flexible dosing options for tarlatamab in relapsed SCLC Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients with previously treated for small cell lung cancer (SCLC), according to results from the randomized Phase 2 DeLLphi-309 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

	New biologic therapy significantly reduces COPD flare-ups in trials Two international clinical trials led in part by researchers at the University of Pittsburgh School of Medicine found that the investigational biologic therapy tozorakimab significantly reduced chronic obstructive pulmonary disease (COPD) flare-ups among patients already receiving standard treatment for the disease compared to patients only receiving standard treatment.

	Tumor DNA clearance reaches 39% in novel immunomodulator and ADC combination The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer (SCLC), according to first clinical data from the ongoing Phase 1b/2 BNT324-01 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

	New AI model decodes chemical signals guiding embryonic cell development As an embryo develops from a small cluster of stem cells, those once "blank slate" cells begin to take on more specialized roles like brain, liver, or muscle cells, and organize themselves into three-dimensional structures such as tissues and organs.

	Neoadjuvant atezolizumab addition quadruples pathological responses in resectable lung tumors Patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median event-free survival of 62.8 months compared with 34.9 months for patients receiving chemotherapy alone, according to final results from the Phase 3 IMpower030 trial.

	High-dose flu vaccine protects older adults with lung disease The risk of being hospitalized for flu or pneumonia can be reduced with a high-dose flu vaccine for older people with chronic lung disease, according to the combined results of two large clinical trials presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain.

Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd.,

Manchester | Sydney

Copyright © 2000-2026